Cell Biotech Co

Cell Biotech Co Pre-Tax Margin

The Pre-Tax Profit Margin of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 21.18 %. In the previous year, Pre-Tax Profit Margin was 31.27 % — a change of -32.27% (lower).

Pre-Tax Margin

21.18 %

YoY

-32.27%

Last updated:

Pre-Tax Profit Margin of Cell Biotech Co is 2025 21.18 % . Pre-Tax Profit Margin of Cell Biotech Co was 2024 31.27 % . It decreases by -32.27% lower compared to the previous year.

The Cell Biotech Co Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
38.15 KRW
Jan 1, 2019
18.08 KRW
Jan 1, 2020
5.27 KRW
Jan 1, 2021
25.79 KRW
Jan 1, 2022
20.13 KRW
Jan 1, 2023
12.79 KRW
Jan 1, 2024
31.27 KRW
Jan 1, 2025
21.18 KRW
The Cell Biotech Co Pre-Tax Margin history
YEARPre-Tax MarginYoY
21.18 %-32.27%
31.27 %+144.50%
12.79 %-36.46%
20.13 %-21.95%
25.79 %+389.38%
5.27 %-70.84%
18.08 %-52.62%
38.15 %+3.03%
37.03 %-4.86%
38.92 %-11.40%
43.93 %+36.94%
32.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Pre-Tax Profit Margin of Cell Biotech Co is 21.18 % in 2025.

Pre-Tax Profit Margin of Cell Biotech Co changed from 31.27 % to 21.18 %, representing a -32.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cell Biotech Co

All Key Metrics — Cell Biotech Co